Response to Comments: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This document is a response to comments on MolDX LCD L39585 and provides the comment period and notice/effective dates but does not contain the LCD's coverage, limitation, documentation, or frequency criteria for molecular biomarker testing for risk stratification of cutaneous squamous cell carcinoma. Manual review of LCD L39585 is required to extract the specific coverage criteria and clinical requirements.

"This notice is a response to comments for MolDX LCD L39585 and records the comment period (06/08/2023–07/22/2023) and notice/effective dates (notice begins 07/04/2024; effective 08/18/2024) but doe..."

Sign up to see full coverage criteria, indications, and limitations.